

Akkadian Partners – Co-founder

Mathieu Bigois

- ▶ Mr Mathieu Bigois is Managing Director and co-founder at Akkadian Partners based in London and Zug
- ▶ Previously Managing Partner of Speria AG (operating under the commercial brand of Ponthieu Partners), a firm he co-founded in 2009 in Zug, Switzerland, focusing on healthcare strategic advisory
- ▶ Until September 2019, Mr Bigois was Venture Partner Europe for Ally Bridge a HK based multi strategy life sciences fund with USD 3 billion Assets under Management. In this capacity he was instrumental in leading Ally Bridge's highly successful participation in the buy out of the KKR stake in Galenica in 2017, as well as the evaluation of major cross border investment opportunities in the biopharmaceuticals, generics, medical technology, aesthetics and luxury sectors
- ▶ Mr. Bigois started his career in 1997 in London at Wasserstein Perella, then moved to the EMEA Healthcare banking groups of Credit Suisse and then Citigroup. He also worked as Chief Financial Officer of the US/French-based specialty biotech Company DrugAbuse Sciences Inc.
- ▶ Mr. Bigois maintains an extensive global network of relationships and routinely executes advisory assignments with developed world as well as select emerging markets players (primarily CIS, Turkey, MENA and Latin America). His client base covers both strategic and financial players in all segments of healthcare
- ▶ Ponthieu Partners has advised major clients such as Elan Pharmaceuticals, Aspen Pharmacare, Biogen Idec, Sanofi, Ramsay Healthcare and Merck Serono, and a large number of private equity and emerging biotech companies.
- ▶ Mr. Bigois is a graduate of Ecole Centrale Paris (MSc. Engineering) and holds an MSc. in Finance and Economics of the London School of Economics (British Council Scholar)



Claude Allary

Strategic advisor


- ▶ Claude Allary is a consultant, senior executive coach and a director of private companies in the pharmaceuticals and biotechnology field.
From 1977 to 2020, he has been working in, and for, industrial and financial Life Sciences companies.
- ▶ From 1977 to 1991 he was active with Sanofi, Pfizer and Glaxo in financial and marketing positions in France and in the UK. From 1991 onwards, he pursued management consulting and coaching activities. Between 2003 and 2020 he was with Bionest Partners (today Accenture Life Sciences) a company he co-founded to become its General Manager, then Senior Advisor.
- ▶ Since 2014, he is a Director of Arch Biopartners, a company quoted on Toronto Stock Exchange, www.archbiopartners.com. Since 2021, he is a Director of Biophytis, a French Biotech company, listed on Euronext and Nasdaq, www.biophytis.com. Between 2013 and 2020, he was a Director of Genethon (Gene Therapy) www.genethon.fr.
- ▶ Claude Allary has been a lecturer at several venues (Management Center Europe, ESSEC, PharmaMiniMBA, Club Galaxy, etc.) and author of many articles, mostly on R&D, strategy and innovation, such as in HBR.
- ▶ Claude Allary is a MBA graduate from ESSEC (1976). He has been a CFA from 2005 to 2011 (Member of the Société Française des Analystes Financiers) and obtained certification for Coaching Senior Executives with Alter et Coach (2011/2013).
- ▶ He holds a Ph.D. in Management Sciences from Université Paris II Panthéon-Assas (2018).



Christian Duchow

Strategic advisor

- ▶ Christian Johannes Kilian Duchow born August 7th, 1967 is a German business Entrepreneur and founder of several Healthcare companies. He is considered a top-level expert in pharmaceutical industry worldwide. Having established an extensive business network, he is keen in identifying business opportunities globally, sourcing the necessary associates and implement the strategic opportunities arising. His leadership is focused on the value of people and his ability to create teams and develop key people within them to achieve the required goals have led to his success throughout the years. Mr. Duchow spends most of his time between Greece, Malta and Germany
- ▶ Mr. Duchow was born in Hamburg, Germany growing up in family owning a small Herbal products manufacturing and trading company. He has spent most of his school vacation in the family business. After high school he went on to study International Logistics in Hamburg
- ▶ In the early 90s he started his career in the chemical-pharmaceutical Industry with one of the major European trading houses. Soon he started cooperating with major pharmaceutical companies as an Executive in Business Development in Germany, Belgium, Switzerland and Greece amongst others. He also became active in business opportunities in Latin America and MENA
- ▶ From the early 2000s, he became part of the Senior Management of several European Pharmaceutical companies including Indukerm Chemie (Swiss), Jubilant (India) and Pharmathen (Greece), across the entire pharma supply chain, covering from the development of the Active Pharmaceutical Ingredient, down to development of the finished product, as well as licensing and marketing in an international context. He has consulted several companies globally, incl. China, Canada, Australia and APAC in business development, constantly travelling around the globe seeking opportunities
- ▶ As a founder and Director of a pharmaceutical compliance company (PharmSol GmbH) he gained the full understanding of Compliance for all manufacturing steps including the logistics under GDP. During his Directorship in the PharmSol group Mr. Duchow advised on Back Integration for the pharmaceutical active ingredients and as well the EU compliance for the manufacturing and supply from Asia Pacific. In 2018 he sold his share to PharmSol
- ▶ In 2003 Mr Duchow founded the company PharOS Greece as a service company advising major Generic Companies worldwide on product development, regulatory affairs and international Business Development. In 2006 PharOS was known as one of the biggest Pharmaceutical Services Provider which he success turned over the coming years into one of the biggest European Generic development and licensing companies. In 2019 he sold his participation in PharOS to a Luxembourg private equity fund
- ▶ During 2016 – 2018 Mr. Duchow was a member of the International committee of the German Pharmaceutical Association supporting the German Industry with his knowledge for the MENA region and Asia Pacific.
- ▶ Currently Mr. Duchow is the co-founder and holds the Director position in two new startup companies in Malta. One is active in the development of new drug delivery systems known as Hybrid products, while the second is focused in the development of Personalized therapies an products based of DNA diagnostics and Bio Informatics. He also takes an interest in Nutraceuticals and Super-foods bridging the World of Pharmaceuticals with the Food Industry



Ross Maclean

Venture partner: Biopharmaceuticals and Generics

- ▶ Dr Ross Maclean, a senior pharmaceutical professional, with almost 30 years of broad exposure at the C-level (Chief Executive Officer, Chief Regulatory Officer) and Senior / Executive Vice President for multinational R&D companies.
- ▶ Dr Maclean has headed multiple Global functions including Manufacturing, R&D, Quality/Analytical, Regulatory Affairs, Pharmacovigilance, Medical Affairs, R&D QA and Quality Compliance departments in multiple organisations in ethical pharmaceutical and generic product companies.
- ▶ Dr Maclean extensive experience includes in particular
 - From May 2018 till April 2021, he was Chief Regulatory Officer and Executive Vice President, Translational Medicine (Manufacturing, R&D, Quality and Compliance), as well as the Data Protection Officer for Sublimity Therapeutics (Dublin, Ireland and Solana Beach, CA, USA).
 - From February 2016 to March 2017, Dr. Maclean held the position of Vice President, Global Regulatory Affairs of Cynapsus Therapeutics Inc., a clinical-stage pharmaceutical company that developed a sublingual formulation of apomorphine [505(b)(2) NDA]. Cynapsus was acquired by Sunovion in August 2016 for US\$624m, with the apomorphine sublingual film (Kynmobi) approved by the FDA in May 2020.
 - From November 2011 to January 2016, Dr. Maclean was an senior executive at Apotex Inc, as the Senior Vice President, Scientific and Regulatory Affairs (Regulatory, Pharmacovigilance, Medical Affairs), a generic pharmaceutical company headquartered in Canada.
 - Dr Maclean previously held positions of Head of Regulatory Affairs at Eidetica, Switzerland (a division of Biogen developing Biosimilars), CEO and Head of development at Drug Abuse Sciences,, San Francisco, US and Paris, France from 2004-2008, developing an intramuscular delivery of naltrexone [505(b)(2) NDA], the VP of Global Regulatory Affairs at SangStat Medical (1999-2003) until the acquisition by Genzyme and multiple positions at ethical and generic companies (Powderject/Chiron, Sanofi, BIOS Consultancy and Generics UK Ltd) earlier in his career.
- ▶ Dr. Maclean completed his BSc (Hons) in Physiology with Pharmacology and his PhD in Pharmacology at Southampton University (UK).



Pierre Morgon

Strategic advisor

- ▶ Pierre A. MORGON is CEO of MRGN Advisors, Executive Vice President, Portfolio Strategy and Supranational Affairs at CanSino Biologics and Regional Partner for Switzerland at Merieux Equity Partners.
- ▶ He is Chairman of the Boards of Eurocine Vaccines, MYCB1, Adiposs, Kupando and Health Technologies Holding, as well as Non-Executive Director to the Boards of Vaccitech, Univercells, Amoeba and Limula.
- ▶ Pierre has over 35 years of experience in the global life science industry, especially with specialty care, vaccines and immunotherapy, at the helm of international operations, in C-level positions at global level in multinational corporations and as CEO of start-up companies.
- ▶ He is a lecturer in several MBA programs in world-class business schools and in life science conferences, and at the Mass Challenge incubator in Switzerland where he is also a mentor for start-up life sciences companies.
- ▶ Pierre holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He is also an alumnus of INSEAD and IMD.

